Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients
Completed · Phase 1 · Has a placebo group
Conditions studied: Primary Hyperoxaluria Type 3
In brief
The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.
Key facts
- Study ID
- NCT04555486
- Run by
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- People needed
- 6
- Starts
- 2020-09-14
- Expected to finish
- 2021-09-07
- Last updated by the study team
- 2024-09-19
Who can join
Age: 6 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Trial Site — Boston, Massachusetts, United States
- Clinical Trial Site — Rochester, Minnesota, United States
- Clinical Trial Site — New York, New York, United States
- Clinical Trial Site — Bonn, Germany
- Clinical Trial Site — Amsterdam, Netherlands
- Clinical Trial Site — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.